Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ASH 2014 /
ASH 2014: Highlights in mantle cell lymphoma

6th - 9th Dec 2014

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 08.12.14
Views: 3565

Prof Steven Le Gouill and Prof Simon Rule

Prof Le Gouill (University Hospital of Nantes, Nantes, France) and Prof Rule (Derriford Hospital, Plymouth, UK) review the data and opinions arising from ASH 2014 about the treatment of mantle cell lymphoma (MCL) for ecancertv. They consider the place of new agents and the best combinations and sequences for utilising them.

The two experts discuss rituximab maintenance after HDCT in younger patients: the results are in favour of maintenance in terms of EFS and PFS. They also discuss the new drugs bortezomib and lenalidomide in combination with chemotherapy in older patients, and debate the implications of the new buzzword "chemo-free."

This programme has been supported by an unrestricted educational grant from Janssen Pharmaceutica (A Johnson & Johnson Company).

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation